Thiazolidinediones: novel treatments for cognitive deficits in mood disorders?

Bibliography

• KESSLER RC, RUBINOW DR, HOLMES C et al.: The epidemiology of DSM-III-R bipolar I disorder in a general population survey. Psychol. Med. (1997) 5(27):1079-1089.
   Google Scholar
• KESSLER R: Comorbidity of unipolar and bipolar depression with other psychiatric disorders in a general population survey. (1999):1-25.
   Google Scholar
• PORTER RJ, GALLAGHER P, THOMPSON JM et al.: Neurocognitive impairment in drug-free patients with major depressive disorder. Br. J. Psychiatry (2003) (182):214-220.
   PubMed Web of Science ®Google Scholar
• MCCALL WV, DUNN AG: Cognitive deficits are associated with functional impairment in severely depressed patients. Psychiatry Res. (2003) 2(121):179-184.
   Google Scholar
• LANDRO NI, STILES TC, SLETVOLD H: Neuropsychological function in nonpsychotic unipolar major depression. Neuropsychiatry Neuropsychol. Behav. Neurol. (2001) 4(14):233-240.
   Google Scholar
• HUGDAHL K, RUND BR, LUND A et al.: Brain activation measured with fMRI during a mental arithmetic task in schizophrenia and major depression. Am. J. Psychiatry (2004) 2(161):286-293.
   Google Scholar
• BEARDEN CE, GLAHN DC, MONKUL ES et al.: Patterns of memory impairment in bipolar disorder and unipolar major depression. Psychiatry Res. (2006) 2-3(142):139-150.
   Google Scholar
• GUALTIERI CT, JOHNSON LG, BENEDICT KB: Neurocognition in depression: patients on and off medication versus healthy comparison subjects. J. Neuropsychiatry Clin. Neurosci. (2006) 2(18):217-225.
   Google Scholar
• DEBATTISTA C: Executive dysfunction in major depressive disorder. Expert Rev. Neurother. (2005) 1(5):79-83.
   Google Scholar
• MALHI GS, LAGOPOULOS J, WARD PB et al.: Cognitive generation of affect in bipolar depression: an fMRI study. Eur. J. Neurosci. (2004) 3(19):741-754.
   Google Scholar
• CLARK L, SARNA A, GOODWIN GM: Impairment of executive function but not memory in first-degree relatives of patients with bipolar I disorder and in euthymic patients with unipolar depression. Am. J. Psychiatry (2005) 10(162):1980-1982.
   Google Scholar
• MACQUEEN GM, GALWAY TM, HAY J et al.: Recollection memory deficits in patients with major depressive disorder predicted by past depressions but not current mood state or treatment status. Psychol. Med. (2002) 2(32):251-258.
   Google Scholar
• DREVETS WC: Neuro-imaging studies of mood disorders. Biol. Psychiatry (2000) 8(48):813-829.
   Google Scholar
• MACQUEEN GM, CAMPBELL S, MCEWEN BS et al.: Course of illness, hippocampal function, and hippocampal volume in major depression. Proc. Natl. Acad. Sci. USA (2003) 3(100):1387-1392.
   Google Scholar
• KONARSKI JZ, MCINTYRE RS, KENNEDY SH et al.: Volumetric neuroimaging in mood disorders: bipolar disorder versus major depressive disorder. Bipolar Disord. (2006) (In Press).
   Google Scholar
• KREBS M, LEOPOLD K, HINZPETER A et al.: Neuroprotective agents in schizophrenia and affective disorders. Expert. Opin. Pharmacother. (2006) 7(7):837-848.
   PubMed Web of Science ®Google Scholar
• LEE AL, OGLE WO, SAPOLSKY RM: Stress and depression: possible links to neuron death in the hippocampus. Bipolar Disord. (2002) 2(4):117-128.
   Google Scholar
• NEU P, BAJBOUJ M, SCHILLING A et al.: Cognitive function over the treatment course of depression in middle-aged patients: correlation with brain MRI signal hyperintensities. J. Psychiatry Res. (2005) 2(39):129-135.
   Google Scholar
• NEUMEISTER A, WOOD S, BONNE O et al.: Reduced hippocampal volume in unmedicated, remitted patients with major depression versus control subjects. Biol. Psychiatry (2005) 8(57):935-937.
   Google Scholar
• DREVETS WC: Neuroimaging abnormalities in the amygdala in mood disorders. Ann. NY Acad. Sci. (2003) (985):420-444.
   PubMedGoogle Scholar
• DREVETS WC: Neuroimaging and neuropathological studies of depression: implications for the cognitive-emotional features of mood disorders. Curr. Opin. Neurobiol. (2001) 2(11):240-249.
   Google Scholar
• SHELINE YI, SANGHAVI M, MINTUN MA et al.: Depression duration but not age predicts hippocampal volume loss in medically healthy women with recurrent major depression. J. Neurosci. (1999) 12(19):5034-5043.
   Google Scholar
• GOULD E, TANAPAT P, MCEWEN BS et al.: Proliferation of granule cell precursors in the dentate gyrus of adult monkeys is diminished by stress. Proc. Natl. Acad. Sci. USA (1998) 6(95):3168-3171.
   Google Scholar
• MCEWEN BS: Mood disorders and allostatic load. Biol. Psychiatry (2003) 3(54):200-207.
   Google Scholar
• MCEWEN BS: Stress and hippocampal plasticity. Ann. Rev. Neurosci. (1999) (22):105-122.
   PubMed Web of Science ®Google Scholar
• WOOD GE, YOUNG LT, REAGAN LP et al.: Stress-induced structural remodeling in hippocampus: prevention by lithium treatment. Proc. Natl. Acad. Sci. USA (2004) 11(101):3973-3978.
   Google Scholar
• GRAY NA, ZHOU R, DU J et al.: The use of mood stabilizers as plasticity enhancers in the treatment of neuropsychiatric disorders. J. Clin. Psychiatry (2003) 64 (Suppl. 5):3-17.
   PubMedGoogle Scholar
• OLNEY JW: Excitotoxicity, apoptosis and neuropsychiatric disorders. Curr. Opin. Pharmacol. (2003) 1(3):101-109.
   Google Scholar
• MATHEW SJ, KEEGAN K, SMITH L: Glutamate modulators as novel interventions for mood disorders. Rev. Bras. Psiquiatr. (2005) 3(27): 243-248.
   Google Scholar
• CARLSON PJ, SINGH JB, ZARATE CA Jr et al.: Neural circuitry and neuroplasticity in mood disorders: insights for novel therapeutic targets. NeuroRx (2006) 1(3):22-41.
   Google Scholar
• DORAISWAMY PM, KRISHNAN KR, OXMAN T et al.: Does antidepressant therapy improve cognition in elderly depressed patients? J. Gerontol. A Biol. Sci. Med. Sci. (2003) 12(58):M1137-M1144.
   Google Scholar
• NEBES RD, POLLOCK BG, HOUCK PR et al.: Persistence of cognitive impairment in geriatric patients following antidepressant treatment: a randomized, double-blind clinical trial with nortriptyline and paroxetine. J. Psychiatry Res. (2003) 2(37):99-108.
   Google Scholar
• BHALLA RK, BUTTERS MA, MULSANT BH et al.: Persistence of neuropsychologic deficits in the remitted state of late-life depression. Am. J. Geriatr. Psychiatry (2006) 5(14):419-427.
   Google Scholar
• LUNA-MEDINA R, CORTES-CANTELI M, ALONSO M et al.: Regulation of inflammatory response in neural cells in vitro by thiadiazolidinones derivatives through peroxisome proliferator-activated receptor-γ activation. J. Biol. Chem. (2005) 22(280):21453-21462.
   Google Scholar
• NATARAJAN C, BRIGHT JJ: Peroxisome proliferator-activated receptor-γ agonists inhibit experimental allergic encephalomyelitis by blocking IL-12 production, IL-12 signaling and Th1 differentiation. Genes Immunol. (2002) 2(3):59-70.
   Google Scholar
• HENEKA MT, KLOCKGETHER T, FEINSTEIN DL: Peroxisome proliferator-activated receptor-γ ligands reduce neuronal inducible nitric oxide synthase expression and cell death in vivo.J. Neurosci. (2000) 18(20):6862-6867.
   Google Scholar
• DELLO RC, GAVRILYUK V, WEINBERG G et al.: Peroxisome proliferator-activated receptor γ thiazolidinedione agonists increase glucose metabolism in astrocytes. J. Biol. Chem. (2003) 8(278):5828-5836.
   Google Scholar
• FUJITA T, SUGIYAMA Y, TAKETOMI S et al.: Reduction of insulin resistance in obese and/or diabetic animals by 5-[4-(1-methylcyclohexylmethoxy)benzyl]-thiazolidine-2,4-dione (ADD-3878, U-63,287, ciglitazone), a new antidiabetic agent. Diabetes (1983) 9(32):804-810.
   Google Scholar
• FEINSTEIN DL: Therapeutic potential of peroxisome proliferator-activated receptor agonists for neurological disease. Diabetes Technol. Ther. (2003) 1(5):67-73.
   Google Scholar
• FEINSTEIN D: Contrasting the neuroprotective and gliotoxic effects of PPARα agonistis. Drug Discov. Today Therap. Strategies (2004) 1(1):29-34.
   Google Scholar
• YKI-JARVINEN H: Thiazolidinediones. N. Engl. J. Med. (2004) 11(351): 1106-1118.
   Google Scholar
• RISNER ME, SAUNDERS AM, ALTMAN JF et al.: Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J. (2006) 6(4):246-254.
   PubMed Web of Science ®Google Scholar
• AOUN P, SIMPKINS JW, AGARWAL N: Role of PPAR-γ ligands in neuroprotection against glutamate-induced cytotoxicity in retinal ganglion cells. Invest. Ophthalmol. Vis. Sci. (2003) 7(44):2999-3004.
   Google Scholar
• COLCA JR: Insulin sensitizers may prevent metabolic inflammation. Biochem. Pharmacol. (2006) 2(72):125-131.
   Google Scholar
• IALENTI A, GRASSIA G, DI MEGLIO P et al.: Mechanism of the anti-inflammatory effect of thiazolidinediones: relationship with the glucocorticoid pathway. Mol. Pharmacol. (2005) 5(67):1620-1628.
   Google Scholar
• URYU S, HARADA J, HISAMOTO M et al.: Troglitazone inhibits both post-glutamate neurotoxicity and low-potassium-induced apoptosis in cerebellar granule neurons. Brain Res. (2002) 2(924):229-236.
   Google Scholar
• FEINSTEIN DL, SPAGNOLO A, AKAR C et al.: Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key? Biochem. Pharmacol. (2005) 2(70):177-188.
   Google Scholar
• SHELINE YI, WANG PW, GADO MH et al.: Hippocampal atrophy in recurrent major depression. Proc. Natl. Acad. Sci. USA (1996) 9(93):3908-3913.
   Google Scholar
• SHELINE YI, SANGHAVI M, MINTUN MA et al.: Depression duration but not age predicts hippocampal volume loss in medically healthy women with recurrent major depression. J. Neurosci. (1999) 12(19):5034-5043.
   Google Scholar
• MUSSELMAN DL, BETAN E, LARSEN H et al.: Relationship of depression to diabetes Types 1 and 2: epidemiology, biology, and treatment.Biol. Psychiatry (2003) 3(54):317-329.
   Web of Science ®Google Scholar
• PAUL IA, SKOLNICK P: Glutamate and depression: clinical and preclinical studies. Ann. NY Acad. Sci. (2003) (1003):250-272.
   PubMedGoogle Scholar
• CRAFT S, WATSON GS: Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol. (2004) 3(3):169-178.
   PubMed Web of Science ®Google Scholar
• MCEWEN BS, MAGARINOS AM, REAGAN LP: Studies of hormone action in the hippocampal formation: possible relevance to depression and diabetes. J. Psychosom. Res. (2002) 4(53):883-890.
   Google Scholar
• SHAPIRO E, BROWN SD, SALTIEL AR et al.: Short-term action of insulin on Aplysia neurons: generation of a possible novel modulator of ion channels. J. Neurobiol. (1991) 1(22):55-62.
   Google Scholar
• MASTERS BA, SHEMER J, JUDKINS JH et al.: Insulin receptors and insulin action in dissociated brain cells. Brain Res. (1987) 2(417):247-256.
   Google Scholar
• SHIBATA S, LIOU SY, UEKI S et al.: Inhibitory action of insulin on suprachiasmatic nucleus neurons in rat hypothalamic slice preparations. Physiol. Behav. (1986) 1(36):79-81.
   Google Scholar
• KONARSKI JZ, MCINTYRE RS, GRUPP LA et al.: Is the cerebellum relevant in the circuitry of neuropsychiatric disorders. J. Psychiatry Neurosci. (2004).
   Google Scholar
• SKEBERDIS VA, LAN J, ZHENG X et al.: Insulin promotes rapid delivery of N-methyl-D-aspartate receptors to the cell surface by exocytosis. Proc. Natl. Acad. Sci. USA (2001) 6(98):3561-3566.
   Google Scholar
• KOPF SR, BARATTI CM: Effects of posttraining administration of insulin on retention of a habituation response in mice: participation of a central cholinergic mechanism. Neurobiol. Learn. Mem. (1999) 1(71):50-61.
   Google Scholar
• FIGLEWICZ DP, SZOT P, ISRAEL PA et al.: Insulin reduces norepinephrine transporter mRNA in vivo in rat locus coeruleus. Brain Res. (1993) 1(602):161-164.
   Web of Science ®Google Scholar
• REGER MA, WATSON GS, FREY WH et al.: Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype. Neurobiol. Aging (2005) 3(27):451-458.
   Google Scholar
• WATSON GS, CHOLERTON BA, REGER MA et al.: Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am. J. Geriatr. Psychiatry (2005) 11(13):950-958.
   Google Scholar
• LUCHSINGER JA, TANG MX, SHEA S et al.: Hyperinsulinemia and risk of Alzheimer disease. Neurology (2004) 7(63):1187-1192.
   Google Scholar
• CRAFT S, PESKIND E, SCHWARTZ MW et al.: Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: relationship to severity of dementia and apolipoprotein E genotype. Neurology (1998) 1(50):164-168.
   Google Scholar
• FROLICH L, BLUM-DEGEN D, BERNSTEIN HG et al.: Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease. J. Neural Transm. (1998) 4-5(105):423-438.
   Google Scholar
• MESSIER C, TEUTENBERG K: The role of insulin, insulin growth factor, and insulin-degrading enzyme in brain aging and Alzheimer's disease. Neural Plast. (2005) 4(12):311-328.
   Google Scholar
• CRAFT S, ASTHANA S, SCHELLENBERG G et al.: Insulin metabolism in Alzheimer's disease differs according to apolipoprotein E genotype and gender. Neuroendocrinology (1999) 2(70):146-152.
   Google Scholar
• BEERI MS, SILVERMAN JM, DAVIS KL et al.: Type 2 diabetes is negatively associated with Alzheimer's disease neuropathology. J Gerontol. A Biol. Sci. Med. Sci. (2005) 4(60):471-475.
   Google Scholar
• HONG M, LEE VM: Insulin and insulin-like growth factor-1 regulate tau phosphorylation in cultured human neurons. J. Biol. Chem. (1997) 31(272):19547-19553.
   Google Scholar
• FREUDE S, PLUM L, SCHNITKER J et al.: Peripheral hyperinsulinemia promotes tau phosphorylation in vivo. Diabetes (2005) 12(54):3343-3348.
   Google Scholar
• SONNTAG WE, RAMSEY M, CARTER CS: Growth hormone and insulin-like growth factor-1 (IGF-1) and their influence on cognitive aging. Ageing Res. Rev. (2005) 2(4):195-212.
   Google Scholar
• BONDY CA, CHENG CM: Signaling by insulin-like growth factor 1 in brain. Eur. J. Pharmacol. (2004) 1-3(490):25-31.
   Google Scholar
• ALEMAN A, DE VRIES WR, DE HAAN EH et al.: Age-sensitive cognitive function, growth hormone and insulin-like growth factor 1 plasma levels in healthy older men. Neuropsychobiology (2000) 2(41):73-78.
   Google Scholar
• ARWERT LI, DEIJEN JB, DRENT ML: The relation between insulin-like growth factor I levels and cognition in healthy elderly: a meta-analysis. Growth Horm. IGF Res. (2005) 6(15):416-422.
   Google Scholar
• KALMIJN S, JANSSEN JA, POLS HA et al.: A prospective study on circulating insulin-like growth factor I (IGF-I), IGF-binding proteins, and cognitive function in the elderly. J. Clin. Endocrinol. Metab. (2000) 12(85):4551-4555.
   Google Scholar
• RESKE-NIELSEN E, LUNDBAEK K: Diabetic encephalopathy. Diffuse and focal lesions of the brain in long-term diabetes. Acta. Neurol. Scand. (1963) (39)(Suppl.):4-90.
   Google Scholar
• FERGUSON SC, BLANE A, WARDLAW J et al.: Influence of an early-onset age of Type 1 diabetes on cerebral structure and cognitive function. Diabetes Care (2005) 6(28):1431-1437.
   Google Scholar
• BRANDS AM, KESSELS RP, DE HAAN EH et al.: Cerebral dysfunction in Type 1 diabetes: effects of insulin, vascular risk factors and blood-glucose levels. Eur. J. Pharmacol. (2004) 1-3(490):159-168.
   Google Scholar
• DEN HEIJER T, VERMEER SE, VAN DIJK EJ et al.: Type 2 diabetes and atrophy of medial temporal lobe structures on brain MRI. Diabetologia (2003) 12(46):1604-1610.
   Google Scholar
• RYAN CM, GECKLE MO, ORCHARD TJ: Cognitive efficiency declines over time in adults with Type 1 diabetes: effects of micro- and macrovascular complications. Diabetologia (2003) 7(46):940-948.
   Google Scholar
• LOBNIG BM, KROMEKE O, OPTENHOSTERT-PORST C et al.: Hippocampal volume and cognitive performance in long-standing Type 1 diabetic patients without macrovascular complications. Diabet. Med. (2006) 1(23):32-39.
   Google Scholar
• PERROS P, DEARY IJ, SELLAR RJ et al.: Brain abnormalities demonstrated by magnetic resonance imaging in adult IDDM patients with and without a history of recurrent severe hypoglycemia. Diabetes Care (1997) 6(20):1013-1018.
   Google Scholar
• FERGUSON SC, BLANE A, PERROS P et al.: Cognitive ability and brain structure in Type 1 diabetes: relation to microangiopathy and preceding severe hypoglycemia. Diabetes (2003) 1(52):149-156.
   Google Scholar
• MUSEN G, LYOO IK, SPARKS CR et al.: Effects of Type 1 diabetes on gray matter density as measured by voxel-based morphometry. Diabetes (2006) 2(55):326-333.
   Google Scholar
• CONVIT A, DE LEON MJ, TARSHISH C et al.: Specific hippocampal volume reductions in individuals at risk for Alzheimer's disease. Neurobiol. Aging (1997) 2(18):131-138.
   Google Scholar
• MCINTYRE RS, KONARSKI JZ, MISENER VL et al.: Bipolar disorder and diabetes mellitus: epidemiology, etiology, and treatment implications. Ann. Clin. Psychiatry (2005) 2(17):83-93.
   Google Scholar
• SHOELSON SE, LEE J, GOLDFINE AB: Inflammation and insulin resistance. J. Clin. Invest. (2006) 7(116):1793-1801.
   Google Scholar
• CERIELLO A: Oxidative stress and diabetes-associated complications. Endocr. Pract. (2006) (12 Suppl. 1):60-62.
   PubMedGoogle Scholar
• HAYLEY S, POULTER MO, MERALI Z et al.: The pathogenesis of clinical depression: stressor- and cytokine-induced alterations of neuroplasticity. Neuroscience (2005) 3(135):659-678.
   Google Scholar
• LICINIO J, WONG ML: The role of inflammatory mediators in the biology of major depression: central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems, and contribute to neurotoxicity and neuroprotection. Mol. Psychiatry (1999) 4(4):317-327.
   PubMed Web of Science ®Google Scholar
• CAPURON L, MILLER AH: Cytokines and psychopathology: lessons from IFN-α. Biol. Psychiatry (2004) 11(56):819-824.
   Google Scholar
• RAISON CL, CAPURON L, MILLER AH: Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. (2006) 1(27):24-31.
   Google Scholar
• YOUNG AH, GALLAGHER P, WATSON S et al.: Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder. Neuropsychopharmacology (2004) 8(29):1538-1545.
   Google Scholar
• SAPOLSKY RM: Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Arch. Gen. Psychiatry (2000) 10(57):925-935.
   Google Scholar
• MCQUADE R, YOUNG AH: Future therapeutic targets in mood disorders: the glucocorticoid receptor. Br. J. Psychiatry (2000) 177:390-395.
   PubMed Web of Science ®Google Scholar
• YOUNG AH: Antiglucocoticoid treatments for depression. Aust. NZ J. Psychiatry (2006) 5(40):402-405.
   Google Scholar
• DORN LD, BURGESS ES, FRIEDMAN TC et al.: The longitudinal course of psychopathology in Cushing's syndrome after correction of hypercortisolism. J. Clin. Endocrinol. Metab. (1997) 3(82):912-919.
   Google Scholar
• FORGET H, LACROIX A, COHEN H: Persistent cognitive impairment following surgical treatment of Cushing's syndrome. Psychoneuroendocrinology (2002) 3(27):367-383.
   Google Scholar
• NEWCOMER JW, SELKE G, MELSON AK et al.: Decreased memory performance in healthy humans induced by stress-level cortisol treatment. Arch. Gen. Psychiatry (1999) 6(56):527-533.
   Google Scholar
• RUSH AJ, GILES DE, SCHLESSER MA et al.: The dexamethasone suppression test in patients with mood disorders. J. Clin. Psychiatry (1996) 10(57):470-484.
   Google Scholar
• CARROLL BJ: Dexamethasone suppression test: a review of contemporary confusion. J. Clin. Psychiatry (1985) 2(Part 2)(46):13-24.
   Google Scholar
• REUS VI, WOLKOWITZ OM: Antiglucocorticoid drugs in the treatment of depression. Expert Opin. Investig. Drugs (2001) 10(10):1789-1796.
   PubMed Web of Science ®Google Scholar
• SUNDARARAJAN S, GAMBOA JL, VICTOR NA et al.: Peroxisome proliferator-activated receptor-γ ligands reduce inflammation and infarction size in transient focal ischemia. Neuroscience (2005) 3(130):685-696.
   Google Scholar
• MORENO S, FARIOLI-VECCHIOLI S, CERU MP: Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS. Neuroscience (2004) 1(123):131-145.
   Google Scholar
• YU K, BAYONA W, KALLEN CB et al.: Differential activation of peroxisome proliferator-activated receptors by eicosanoids. J. Biol. Chem. (1995) 41(270):23975-23983.
   Google Scholar
• PARKER G, GIBSON NA, BROTCHIE H et al.: ω-3 fatty acids and mood disorders. Am. J. Psychiatry (2006) 6(163):969-978.
   Google Scholar
• RAVEN PW, TAYLOR NF: 11β-HSD and 17β-HSD as biological markers of depression: sex differences and correlation with symptom severity. Endocr. Res. (1998) 3-4(24):659-662.
   Google Scholar
• DESBRIERE R, VUAROQUEAUX V, ACHARD V et al.: 11β-hydroxysteroid dehydrogenase type 1 mRNA is increased in both visceral and subcutaneous adipose tissue of obese patients. Obesity (Silver, Spring) (2006) 5(14):794-798.
   Google Scholar
• GELINAS DS, LAMBERMON MH, MCLAURIN J: Ciglitazone increases basal cytokine expression in the central nervous system of adult rats. Brain Res. (2005) 1-2(1034):139-146.
   Google Scholar
• LANDRETH GE, HENEKA MT: Anti-inflammatory actions of peroxisome proliferator-activated receptor γ agonists in Alzheimer's disease. Neurobiol. Aging (2001) 6(22):937-944.
   Google Scholar
• CARDENAS A, MORO MA, HURTADO O et al.: Dual role of nitric oxide in adult neurogenesis. Brain Res. Brain Res. Rev. (2005) 1(50):1-6.
   Google Scholar
• JIN K, ZHU Y, SUN Y et al.: Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo.Proc. Natl. Acad. Sci. USA (2002) 18(99):11946-11950.
   Google Scholar
• VODOVOTZ Y, LUCIA MS, FLANDERS KC et al.: Inducible nitric oxide synthase in tangle-bearing neurons of patients with Alzheimer's disease. J. Exp. Med. (1996) 4(184):1425-1433.
   Google Scholar
• LI M, PASCUAL G, GLASS CK: Peroxisome proliferator-activated receptor γ-dependent repression of the inducible nitric oxide synthase gene. Mol. Cell Biol. (2000) 13(20):4699-4707.
   Google Scholar
• PEREIRA MP, HURTADO O, CARDENAS A et al.: The nonthiazolidinedione PPARγ agonist L-796,449 is neuroprotective in experimental stroke. J. Neuropathol. Exp. Neurol. (2005) 9(64):797-805.
   Google Scholar
• SHIMAZU T, INOUE I, ARAKI N et al.: A peroxisome proliferator-activated receptor-γ agonist reduces infarct size in transient but not in permanent ischemia. Stroke (2005) 2(36):353-359.
   Google Scholar
• ZHAO Y, PATZER A, GOHLKE P et al.: The intracerebral application of the PPARγ-ligand pioglitazone confers neuroprotection against focal ischaemia in the rat brain. Eur. J. Neurosci. (2005) 1(22):278-282.
   Google Scholar
• SMITH SA, MONTEITH GR, HOLMAN NA et al.: Effects of peroxisome proliferator-activated receptor γ ligands ciglitazone and 15-deoxy-δ 12,14-prostaglandin J2 on rat cultured cerebellar granule neuronal viability. J. Neurosci. Res. (2003) 6(72):747-755.
   Google Scholar
• LUO Y, YIN W, SIGNORE AP et al.: Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptor-γ agonist rosiglitazone. J. Neurochem. (2006) 2(97):435-448.
   Google Scholar
• COLLINO M, ARAGNO M, MASTROCOLA R et al.: Modulation of the oxidative stress and inflammatory response by PPAR-γ agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusion. Eur. J. Pharmacol. (2006) 1-2(530):70-80.
   Google Scholar
• VILLEGAS I, MARTIN AR, TOMA W et al.: Rosiglitazone, an agonist of peroxisome proliferator-activated receptor γ, protects against gastric ischemia-reperfusion damage in rats: role of oxygen free radicals generation. Eur. J. Pharmacol. (2004) 1-3(505):195-203.
   Google Scholar
• LI XM, CHLAN-FOURNEY J, JUORIO AV et al.: Differential effects of olanzapine on the gene expression of superoxide dismutase and the low affinity nerve growth factor receptor. J. Neurosci. Res. (1999) 1(56):72-75.
   Google Scholar
• OHNISHI T, MATSUDA H, TABIRA T et al.: Changes in brain morphology in Alzheimer disease and normal aging: is Alzheimer disease an exaggerated aging process? AJNR Am. J. Neuroradiol. (2001) 9(22):1680-1685.
   Google Scholar
• RYAN CM, FREED MI, ROOD JA et al.: Improving metabolic control leads to better working memory in adults with Type 2 diabetes. Diabetes Care (2006) 2(29):345-351.
   Google Scholar
• CHARBONNEL B, DORMANDY J, ERDMANN E et al.: The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients. Diabetes Care (2004) 7(27):1647-1653.
   Google Scholar